Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress
This trial is active, not recruiting.
|Condition||coronary artery disease|
|Treatments||rest/dipyridamole stress rb-82 myocardial perfusion pet/ct, rest/lexiscan(tm) stress rb-82 myocardial perfusion pet|
|Sponsor||Cardiovascular Imaging Technologies|
|Collaborator||Astellas Pharma US, Inc.|
|Start date||December 2008|
|End date||December 2010|
|Trial size||32 participants|
|Trial identifier||NCT00808314, 08-271|
Lexiscan(TM) has ideal properties for Rb-82 PET imaging and the stress response it invokes may offer multiple advantages for the diagnosis of coronary disease and functional abnormalities. The goal of this investigation is to establish quantitative equivalence of Lexiscan(TM) rest/stress Rb-82 PET images to dipyridamole rest/stress images.
|Intervention model||parallel assignment|
Quantitative analysis of local and regional myocardial perfusion between Lexiscan(TM) and dipyridamole rest/stress Rb82 PET
time frame: 12 months
Male or female participants from 35 years up to 90 years old.
Inclusion Criteria: - BMI <35 - No intervention or change in management between dipyridamole and Lexiscan(TM) PET Exclusion Criteria: - BMI >35 - An intervention or change in management between dipyridamole and Lexiscan(TM) PET
|Official title||Lexiscan(TM) Rb-82 Myocardial Perfusion Positron Emission Computed Tomography: A Comparison With Dipyridamole|
|Principal investigator||Timothy M Bateman, MD|
Call for more information